Share this video  

ASCO 2020 | Updates from COMBI-AD: dabrafenib and trametinib for melanoma

Axel Hauschild, MD, of the University of Schleswig-Holstein, Kiel, Germany, outlines five-year analysis of COMBI-AD (NCT01682083), a study evaluating the long-term benefit of adjuvant dabrafenib and trametinib in patients with resected stage III BRAF V600–mutant melanoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).